Lexaria Bioscience Announces 1-for-15 Reverse Stock Split to Restore NASDAQ Compliance

What Happened

• Lexaria Bioscience Corp. announced a 1-for-15 reverse stock split of its common stock, effective 12:01 a.m. ET on August 3, 2026. The Company filed a Certificate of Change with the Nevada Secretary of State on July 29, 2026 and the split will be reflected in trading at the open on August 3, 2026. The ticker will remain LEXX on NASDAQ but the CUSIP will change to 52886N604.

Key Details

• Authorized shares will be reduced from 220,000,000 to 14,666,667 (1-for-15 ratio).
• Outstanding shares will be reduced from 24,787,446 to approximately 1,652,518 (subject to rounding adjustments).
• No fractional shares will be issued; instead the Company will issue one whole post-split share to any stockholder who would otherwise receive a fractional share.
• Outstanding options and warrants will be adjusted to reflect the reverse split. Stockholders holding shares in brokerage accounts need take no action; certificated holders may contact Computershare (transfer agent) for certificate exchange.

Why It Matters

• The reverse split was implemented primarily to help Lexaria regain compliance with NASDAQ Capital Market listing standards and secondarily to stabilize trading and support business development efforts. The split reduces the share count and increases the per‑share basis but does not materially change each holder’s percentage ownership or voting power (aside from minor rounding effects). Retail investors should note the effective date (Aug 3, 2026), the new CUSIP, and that no shareholder vote was required because the board approved the change under Nevada law.